Opinion: Science is Utah's quiet engine — don't stall it with cuts to important funding
Science quietly powers Utah's prosperity. From lifesaving diagnostics at ARUP Laboratories and cutting-edge biotech startups to clean energy research at Utah State and drought-resistant crops developed through university partnerships, science is behind much of what makes life in Utah better, longer and more secure.
In 2024, the National Institutes of Health (NIH) awarded over $300 million to Utah institutions. That funding supported thousands of jobs, helped launch companies, and enabled groundbreaking research in everything from cancer treatments to Alzheimer's to rare disease therapies. Public health advances that benefit every Utahn — urban or rural — almost always begin through federally funded research.
But now, that progress is in jeopardy.
Proposed cuts and restrictions to NIH funding could have devastating effects on Utah's research institutions and economy. The plan to slash NIH's overall budget by nearly half, coupled with a proposal to reduce the indirect cost reimbursement to universities from around 50% to 15%, would mean far less money to cover the real costs of doing science. Basics like lab space, utilities, data storage and administrative support aren't luxuries — they're the infrastructure that makes research possible.
For public universities like the University of Utah and Utah State, this isn't just a budget concern. It's a structural threat. Without adequate indirect cost support, universities would either have to drastically scale back research activity or shift the financial burden to students and state taxpayers. Both options would weaken Utah's competitive edge in science and technology.
The consequences would ripple far beyond campus. Utah is known for its 'Industry' motto — a title that honors the resourcefulness and hard work that built our communities. Today, that industrious spirit thrives in our biotech labs, clean tech startups and health research centers. But industries can't thrive without innovation. Utah's life sciences sector depends on a steady pipeline of NIH-supported talent and discoveries emerging from research. Companies like Recursion, Myriad Genetics and BioFire Diagnostics thrive because of academic partnerships and access to skilled graduates. Pulling funding would slow innovation and shrink the talent pool.
But it's not just about economics. It's about people.
NIH funding supports clinical trials that help Utah families battling cancer. It funds suicide prevention programs in our schools, mental health outreach in rural counties, and pediatric care innovations at Primary Children's Hospital (PCH). It supports research for Native American communities and families dealing with chronic conditions like diabetes and asthma. Without that funding, many of these programs would disappear.
I've seen the impact of public health investment firsthand. After I tested positive for latent tuberculosis as a student, I received free weekly treatment and health monitoring through the Utah County Health Department. It was science-backed care, delivered through a local system supported by federal resources. Without that treatment, I could have developed active tuberculosis — a threat not just to me but also to others. The system worked because it was built on scientific research and proactive policy. That kind of safety net doesn't happen without sustained funding.
Furthermore, my nephew, Wesley, was cared for at PCH when he was just four months old. He was diagnosed with polyarteritis nodosa, a rare autoimmune disease that causes inflammation and damage to the heart. The NIH not only funds various programs at PCH but also was crucial to backing the science that led to properly diagnosing and saving Wesley.
These cuts hurt the next generation. Graduate students and early career scientists — many of whom come from Utah — rely on federal research grants to get their start. If funding dries up, so do those opportunities. We risk losing promising young minds to other careers or other countries.
This is not a partisan issue. Scientific progress should never be about politics. Every Utahn benefits from the medications they take, the clean water they drink, the safe food they eat and the medical care they receive. All of these are underpinned by science. Restricting it weakens our shared safety net and quality of life.
Utah is built on hard work, innovation and foresight. Cutting science funding now would undermine the very foundation that allows us to adapt, compete and care for our communities. Science works for Utah — let's keep it that way.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
2 hours ago
- New York Post
Study reveals major health upside of going through menopause later
Most women can't wait to give Aunt Flo the boot. After all, she's moody, messy and shows up uninvited every month. But new research suggests that having more years between your first period and your last comes with some serious health perks later in life. And it has nothing to do with what's happening below the belt. 4 When women enter menopause, they stop menstruating and can no longer get pregnant naturally. Syda Productions – In the study, University of Auckland researchers analyzed brain scans from more than 1,000 postmenopausal women and spotted a striking pattern. Those who got their first period earlier, went through menopause later or simply had more years in between showed noticeably slower signs of brain aging. 'These findings support the idea that estradiol — the most potent and prevalent form of estrogen during a woman's reproductive years — may help protect the brain as it ages,' said Dr. Eileen Lueders, lead researcher of the study. In animal studies, estradiol has been found to support brain health by enhancing neuroplasticity, reducing inflammation and improving communication between brain cells. 4 Women are disproportionately affected by Alzheimer's disease. kangwan – Estradiol levels fluctuate throughout a woman's life. They rise sharply at puberty, stay high during most of the reproductive years, then drop steeply around menopause. Previous studies have linked that decline in estradiol levels to an increased risk of dementia and other age-related brain conditions. The findings suggest that health interventions, such as hormone treatment, in the years leading up to menopause and immediately after could help combat an increased risk of Alzheimer's for some women, researchers said. The stakes are high: Women bear the brunt of the memory-robbing disease, making up about two-thirds of the 7 million cases across the US today, according to the Alzheimer's Association. 4 A first period is typically a sign that a girl is nearing the end of puberty. Sarah Rypma – In the US, girls usually start menstruating around age 12, though the Mayo Clinic reports that periods can begin as early as 8 or as late as 16. The years when a woman menstruates and can get pregnant are called the reproductive phase. This stage ends with menopause, which is officially diagnosed after a woman has gone 12 months without a period. The average women in the US hits menopause around age 51, but it can happen anytime from the 30s to the mid-50s or later, according to the federal Office on Women's Health. The age you enter menopause is influenced by several factors, including genetics, lifestyle and certain medical conditions. For example, women who smoke may enter menopause earlier, while having multiple pregnancies can delay its onset. 4 The years leading up to menopause are often accompanied by uncomfortable symptoms like hot flashes. Monkey Business – 'As more women weigh the benefits of hormone therapy during menopause, findings like these spark important conversations and open the door to more inclusive, focused research in women's brain health,' said Alicja Nowacka, a PhD student at the University of Auckland who wasn't involved in the study. While the new research adds to the growing evidence that estradiol may help protect brain health, Lueders cautioned that the effects were small and estradiol levels were not directly measured. She also noted that other factors, such as genetics, lifestyle and overall health, can play a role in brain aging. Looking ahead, Lueders is urging future studies to include a more diverse pool of participants and directly measure their hormone levels to better understand how estradiol and other factors impact women's brain health.
Yahoo
4 hours ago
- Yahoo
Amazon.com (NasdaqGS:AMZN) Expands AWS Presence With US$5 Billion Data Center Investment In Taiwan
recently announced the launch of its AWS Asia Pacific (Taipei) Region, highlighting a $5 billion investment in data center infrastructure. This expansion, coupled with a $10 billion investment in North Carolina to bolster AI and cloud computing capabilities, underscores Amazon's commitment to innovation and business growth. These significant developments align with Amazon's overall strategic objectives and may enhance its market position. The company's share price rose 13% over the past month, coinciding with the market's general upward trend, which experienced a 13% rise over the past year across the broader market. Buy, Hold or Sell View our complete analysis and fair value estimate and you decide. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent developments regarding Amazon's investments in the AWS Asia Pacific (Taipei) Region and North Carolina can significantly influence the company's operational strategy, furthering its drive towards AI and cloud computing capabilities. These initiatives are expected to enhance revenue streams, aligning with the company's narrative of optimizing efficiency through advanced technologies. Over the three-year timeframe, Amazon's total shareholder return, inclusive of share price and dividends, achieved a 94.77% increase. Within the past year, Amazon's share price rise of 13% outpaced the broader market's 12.6% gain, reflecting robust performance despite prevailing industry challenges. In light of Amazon's stated commitments, analysts have projected revenue growth of 8.9% per annum, bolstered by both traditional and AI-driven cloud services. Earnings prospects are anticipated to rise to US$103.6 billion by 2028, up from US$65.94 billion today. While these expansions present opportunities for substantial revenue increases, the pressure from infrastructure investments must be carefully managed to sustain growth expectations. With a current share price of US$185.01, the 22.7% higher analyst price target of US$239.33 illustrates an optimistic market consensus. However, investors are advised to consider both market risks and the variations in analyst predictions when evaluating Amazon's future prospects. Unlock comprehensive insights into our analysis of stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:AMZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
IREN (NasdaqGS:IREN) Surges 48% in One Month After Strong Q3 Earnings
IREN recently reported strong third-quarter financial results, with a marked increase in sales and net income compared to the previous year, which stands out as a potential influence on the company's impressive 48% share price rise over the past month. While this growth in earnings is notable, the overall market environment also played a role, with a 1.8% market rise over the last seven days and a 13% increase over the past 12 months. Although IREN's nine-month results reveal ongoing challenges, recent positive earnings may have bolstered investor confidence, adding weight to the broader market's upward trend. We've spotted 3 weaknesses for IREN you should be aware of, and 2 of them are a bit concerning. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent strong quarterly earnings announcement for IREN (NasdaqGS:IREN) underscores the company's efforts to reshape its business strategy amid changing market conditions. The shift from primarily focusing on volatile cryptocurrency mining to expanding AI and cloud infrastructure could potentially stabilize earnings and boost margins over the long term. This business transformation is echoed in the robust total shareholder return of 102.28% over the past three years, showcasing a significant appreciation in shareholder value. Despite this impressive growth, IREN's shares have underperformed the US Software industry, which saw a 22.6% increase over the last year, highlighting the challenges inherent in its core operations. As IREN pivots towards new growth catalysts like the Childress and Sweetwater projects, the potential for revenue growth remains strong, driven by global demand for digital infrastructure. Analysts forecast a revenue growth of 52.0% annually over the next three years, suggesting promising prospects for near-future profitability transformation. It is essential to consider the recent share price increase in relation to the consensus analyst price target of US$18.52, which exceeds the current price of US$8.89 by 52.0%. This differential indicates a substantial potential for upward revaluation if IREN achieves forecasted growth targets. However, the company's reliance on crypto mining and its ambitious expansion introduce unavoidable risks that could impact these valuations. As always, investors should weigh both the opportunities and uncertainties when considering the company's future trajectory. Our comprehensive valuation report raises the possibility that IREN is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:IREN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio